BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 2, 2026
Home » Authors » Anette Breindl

Articles by Anette Breindl

Gloved hand holding petri dish in lab

Protein introns, "inteins", are antifungal targets

Jan. 5, 2021
By Anette Breindl
Researchers from the State University of New York at Albany have identified small molecules that could inhibit intein self-splicing from the protein PrP8 in the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii, emerging pathogens that can cause fungal meningitis in immunocompromised patients.
Read More
Mycobacterium tuberculosis
Bench Press

Killing Mycobacterium tuberculosis, some assembly required

Jan. 4, 2021
By Anette Breindl
BioWorld looks at translational medicine, including: Liver metastases are immunosuppressive.
Read More
Microscope
Bench Press

Innate immunity without autoimmunity

Dec. 31, 2020
By Anette Breindl
BioWorld looks at translational medicine.
Read More
Digital cancer cells illustration

Atlas maps cleaned-up tumor microbiomes

Dec. 31, 2020
By Anette Breindl
Researchers at Duke University have developed a set of methods to separate out microbial contamination from microbiome species that were part of tumors and used those methods to gain new insights into tumor microbiomes. 
Read More
Product image

Interscope receives FDA de novo marketing authorization for direct endoscopic necrosectomy, inks Micro-Tech Endoscopy agreement

Dec. 30, 2020
By Anette Breindl
The U.S. FDA granted de novo marketing authorization to Interscope Inc.’s Endorotor system for direct endoscopic necrosectomy (DEN) of walled-off pancreatic necrosis, giving the specialty device a cutting edge over more generic tools often used for the challenging procedure. Endorotor received a CE mark for this indication in 2018 and also has FDA 510(k) clearance for post-endoscopic mucosal resection tissue persistence with a scarred base and for removal of endobronchial tumors and granulation tissue.
Read More
Coronavirus mutation illustration
Mask up

COVID anniversary coincides with advent of more transmissible variants

Dec. 30, 2020
By Anette Breindl
It has been a year since Wuhan health authorities first issued a bulletin about a cluster of pneumonia cases of unknown cause, first bringing what would become the COVID-19 pandemic to the attention of the World Health Organization. Now, a mutation that significantly increases SARS-CoV-2’s transmissibility has been detected in the U.S. On Dec. 29, Colorado public health authorities reported the first known case of infection with the SARS-CoV-2 VUI 202012/01 (Variant Under Investigation, year 2020, month 12, variant 01), also called B.1.1.7, variant in the U.S. The patient in question, a male in his 20s, has not traveled internationally, indicating that the variant is already circulating more widely in the U.S.
Read More
Brain, illustrating pain/injury
Bench Press

Brain defense without swelling

Dec. 29, 2020
By Anette Breindl
BioWorld looks at translational medicine.
Read More
Condensate with individual protein molecules

Condensates offer broad vistas for Faze Medicines

Dec. 29, 2020
By Anette Breindl
Startup Faze Medicines Inc. launched in early December with a series A funding of $81 million, and an A list of investors, led by Third Rock Ventures – an indicator of the attention condensates are attracting from the biopharma industry. Faze CSO Rachel Meyers, though, named another indicator for condensates’ blue-ribbon status: rumors have it that the 7th edition of Molecular Biology of the Cell – a workhorse textbook for 30 years’ worth of students in the field – will be the first to include information on condensates.
Read More

BioWorld MedTech’s Oncology Extra for Dec. 22, 2020

Dec. 22, 2020
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology, including: Multicancer screening paradigm bolstered in new study; Potentiating PARP inhibitors; New non-viral vector siRNA approach described; NICE nods to combo therapy for HCC.
Read More
Lung cancer illustration

Tumors, metastases activate mTOR in different ways

Dec. 21, 2020
By Anette Breindl
Investigators at KU Leuven have discovered that although mTOR signaling was important in primary breast tumors and lung metastases alike, the signals that activated mTOR were different between the two, and mTOR signaling could be inhibited through different mechanisms.
Read More
Previous 1 2 … 65 66 67 68 69 70 71 72 73 … 399 400 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • IMV-101 shows promise for B-cell malignancies

    BioWorld Science
    IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing